当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry.

Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry.

Abstract：

:This 5-year, prospective registry enrolled 600 lower-risk MDS patients (pts) with transfusional iron overload. Clinical outcomes were compared between chelated and nonchelated pts. At baseline, cardiovascular comorbidities were more common in non-chelated pts, and MDS therapy was more common in chelated pts. At 24 months, chelation was associated with longer median overall survival (52.2 months vs. 104.4 months; p<.0001) and a trend toward longer leukemia-free survival and fewer cardiac events. No differences in safety were apparent between groups. Limitations of this analysis included, varying time from diagnosis and duration of chelation, and the fact that the decision to chelate may have been influenced by pt clinical status.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Lyons RM,Marek BJ,Paley C,Esposito J,Garbo L,DiBella N,Garcia-Manero G

doi

10.1016/j.leukres.2013.11.004

subject

Has Abstract

pub_date

2014-02-01 00:00:00

pages

149-54

issue

2

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(13)00392-5

journal_volume

38

pub_type

杂志文章,多中心研究

相关文献

LEUKEMIA RESEARCH文献大全
  • Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy.

    abstract：:We investigated protracted low-dose oral Clofarabine for the treatment of myelodysplastic syndromes (MDS). Adults with an International Prognostic Scoring System (IPSS) score of INT-1 or higher who had failed first line therapy were eligible. INT-1 patients had to be transfusion-dependent. We started with oral Clofara...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.05.004

    authors： Rudrapatna VK,Morley K,Boucher KM,Pierson AS,Shull CT,Kushner JP,Shami PJ

    更新日期：2015-08-01 00:00:00

  • Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL).

    abstract：:Defective apoptosis is a hallmark of the progression of B chronic lymphocytic leukaemia (B-CLL). Smac-mimetics have been shown to induce apoptosis in several tumours. We describe the in vitro pro-apoptotic activity and regulation of the molecular pathway induced by new Smac-mimetics in B-CLL. The cytotoxic effect was ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2013.03.016

    authors： Scavullo C,Servida F,Lecis D,Onida F,Drago C,Ferrante L,Seneci P,Barcellini W,Lionetti M,Todoerti K,Neri A,Delia D,Deliliers GL

    更新日期：2013-07-01 00:00:00

  • Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region.

    abstract：:Acute myeloid leukemia is an aggressive disease that arises from clonal expansion of malignant hematopoietic precursor cells of the bone marrow. Deletions on the long arm of chromosome 9 (del(9q)) are observed in 2% of acute myeloid leukemia patients. Our deletion analysis in a cohort of 31 del(9q) acute myeloid leuke...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2018.11.007

    authors： Naarmann-de Vries IS,Sackmann Y,Klein F,Ostareck-Lederer A,Ostareck DH,Jost E,Ehninger G,Brümmendorf TH,Marx G,Röllig C,Thiede C,Crysandt M

    更新日期：2019-01-01 00:00:00

  • Characterization of the AKR thymic microenvironment and its influence on thymocyte differentiation and lymphoma development.

    abstract：:The thymic stroma has long been implicated in AKR thymic leukaemia. In this study an extensive panel of monoclonal antibodies was used to investigate changes in the AKR thymic microenvironment, in parallel with thymocyte differentiation of normal (2 month), preleukaemic (5-7 month) and leukaemic (> 7 month) mice. We f...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(95)00102-6

    authors： Davey GM,Tucek-Szabo CL,Boyd RL

    更新日期：1996-10-01 00:00:00

  • Hemopoietic features of splenectomized mice bearing IL-3 producing T cell leukemia.

    abstract：:Hemopoietic responses were studied in splenectomized mice after transplantation of the hemopoietic colony stimulating activity producing leukemia, L8313. In non-splenectomized mice, the number of peripheral leukocytes was elevated to 4 x 10(5)/mm3 after transplantation. In contrast, it was below 1.7 x 10(4)/mm3 in spl...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(89)90159-8

    authors： Sawada H,Sugimoto K,Aramaki K,Mori KJ

    更新日期：1989-01-01 00:00:00

  • New therapeutics for myelodysplastic syndromes.

    abstract：:While MDS was only recently viewed as an orphan disease without any FDA approved therapeutic options, the landscape has changed dramatically with a promise for development of exciting new therapeutics that parallels our growing understanding of the pathobiology of the disease. An array of new agents is entering clinic...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2012.08.010

    authors： List AF

    更新日期：2012-12-01 00:00:00

  • Detection of fos oncogene products by monoclonal antibody FO-120 in lymphoproliferative disorders.

    abstract：:We investigated the expression of fos oncogene proteins in lymphoproliferative disorders, using a monoclonal antibody (FO-120) that was prepared against a synthetic oligopeptide of fos protein (amino acid sequence from 127 to 152). Although peripheral blood leukocytes were rarely positive for FO-120, they were transie...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(89)90010-6

    authors： Kanaitsuka T,Namba Y,Zu YL,Ishii K,Ashihara T,Hanaoka M,Suchi T

    更新日期：1989-01-01 00:00:00

  • Induction of mixed allogeneic chimerism for leukemia.

    abstract：:Hybrid (C56BL/6 x DBA) (BDF1; H-2b/H-2d) mice bearing the P815 leukemia (H-2d) were grafted with a (CBA x C57BL/6)F1 (CBF1; H-2k/H-2b) cell suspension, comprising bone marrow cells (BMC; 25 x 10(6)/mouse) and spleen cells (SC; 55 x 10(6)/mouse) on day-4, then treated with cyclophosphamide (200 mg/kg) on day-2 and fina...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(97)00011-8

    authors： Seledtsov VI,Seledtsova GV,Avdeev EV,Samarin DM,Kozlov VA

    更新日期：1997-10-01 00:00:00

  • Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571.

    abstract：:Resistance to chronic myeloid leukemia (CML) drug STI571 has been associated with point mutations in the kinase domain of BCR-ABL. For example, the mutation T315I (g. 68721C>T) and, to a lesser extent, Y253F (g. 58796A>T) appear in a significant proportion of patients resistant to treatment. Mutations appear intimatel...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(03)00066-3

    authors： Liu WH,Makrigiorgos GM

    更新日期：2003-11-01 00:00:00

  • The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine.

    abstract：:HSP90 is a multi-client chaperone involved in regulating a large array of cellular processes and is commonly overexpressed in many different cancer types including hematological malignancies. Inhibition of HSP90 holds promise for targeting multiple molecular abnormalities and is therefore an attractive target for hete...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.03.016

    authors： Lazenby M,Hills R,Burnett AK,Zabkiewicz J

    更新日期：2015-06-01 00:00:00

  • Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).

    abstract：:Homoharringtonine combined aclarubicin and cytarabine (HAA) has been demonstrated to achieve a high remission rate and provide a survival advantage in acute myeloid leukemia (AML). To investigate whether HAA is an ideal induction regimen for t(8;21)AML, we retrospectively analyzed the data of 140 patients from the las...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2016.02.012

    authors： Zhu HH,Jiang H,Jiang Q,Jia JS,Qin YZ,Huang XJ

    更新日期：2016-05-01 00:00:00

  • Iron chelators induce autophagic cell death in multiple myeloma cells.

    abstract：:We examined the antineoplastic effects of the iron chelators, deferasirox and deferoxamine in multiple myeloma cell lines as well as primary myeloma cells. These iron chelators showed marked antiproliferative activity as well as cytotoxicity toward myeloma cell lines and deferasirox was cytotoxic to bone marrow plasma...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2014.06.005

    authors： Pullarkat V,Meng Z,Donohue C,Yamamoto VN,Tomassetti S,Bhatia R,Krishnan A,Forman SJ,Synold TW

    更新日期：2014-08-01 00:00:00

  • Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.

    abstract：:Five patients from the Kyushu area in Japan with adult T-cell leukaemia (ATL) refractory to conventional chemotherapeutic agents were treated with 5 mg/m2 of the adenosine deaminase inhibitor, 2'-deoxycoformycin (DCF), intravenously (i.v.) for 3 consecutive days, followed by 5 mg/m2 i.v. weekly. Two patients showed a ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(86)90251-1

    authors： Yamaguchi K,Yul LS,Oda T,Maeda Y,Ishii M,Fujita K,Kagiyama S,Nagai K,Suzuki H,Takatsuki K

    更新日期：1986-01-01 00:00:00

  • Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors.

    abstract：:We investigated the possible influence of recombinant (r) sIL-6R on the growth of three IL-6 non-responsive or weakly IL-6 responsive long-term myeloma cell lines. The three cell lines chosen for the study (U266, L363 and Fravel) all expressed gp130 but differed in their expression of IL-6R and IL-6. mRNA analysis by ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(95)00077-1

    authors： Diamant M,Hansen MB,Rieneck K,Svenson M,Yasukawa K,Bendtzen K

    更新日期：1996-04-01 00:00:00

  • Hierarchical regulation of interleukin production: induction of interleukin 6 (IL-6) production from bone marrow cells and marrow stromal cells by interleukin 3 (IL-3).

    abstract：:IL-3 stimulated the production of IL-6 from a bone marrow-adherent cell population, macrophages and from hemopoietic supportive stromal cell lines. It also induced IL-6 production from a stem cell-enriched population of bone marrow cells which did not produce IL-6 without stimulation. In contrast, stimulation with IL-...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(91)90180-2

    authors： Miyashita M,Sugimoto K,Suzuki J,Taniguchi S,Aramaki K,Mori KJ

    更新日期：1991-01-01 00:00:00

  • Clinical features and outcome of T-lineage acute lymphoblastic leukemia in adults: a low initial white blood cell count, as well as a high count predict decreased survival rates.

    abstract：:Although biological and clinical features differ between B-lineage acute lymphoblastic leukemia (ALL) and T-lineage ALL (T-ALL), there have been few reports that focused on the prognosis for T-ALL in adults, primarily due to its rarity. Here, we studied the long-term outcomes and prognostic factors specific for adult ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.08.004

    authors： Yanada M,Jinnai I,Takeuchi J,Ueda T,Miyawaki S,Tsuzuki M,Hatta Y,Usui N,Wada H,Morii T,Matsuda M,Kiyoi H,Okada M,Honda S,Miyazaki Y,Ohno R,Naoe T

    更新日期：2007-07-01 00:00:00

  • Production of interleukin-3 from a T-cell neoplasm.

    abstract：:We have established a new T-cell line (CL-8313) that produces interleukin-3 from the spleen cells of mice with a radiation-induced myeloproliferative disorder. IL-3 activity was detected at an extremely high level in the culture medium of the CL-8313 cell line in the absence of any exogenous stimulator. A large amount...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(88)90005-7

    authors： Yoshida K,Seki M,Maeda M,Fujita J,Tadokoro K

    更新日期：1988-01-01 00:00:00

  • A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.

    abstract：:Oblimersen selectively targets Bcl-2 mRNA and has been shown to enhance the apoptotic activity of various antileukemic agents, including gemtuzumab ozogamicin (GO), in preclinical studies. We evaluated the efficacy and safety of oblimersen combined with GO in patients > or =60 years of age in first relapse with CD33+ ...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2005.10.025

    authors： Moore J,Seiter K,Kolitz J,Stock W,Giles F,Kalaycio M,Zenk D,Marcucci G

    更新日期：2006-07-01 00:00:00

  • Pluripoietin effects on CFU-S lineage determination: possible mechanisms.

    abstract：:Regulation of pluripotent stem cell (CFU-S) proliferation kinetics by humoral factors is now well documented. However, the mechanism of choice of CFU-S differentiation pathways is still a controversial issue. We suggest that long-range humoral factors (pluripoietins) are capable of preferentially channelling CFU-S tow...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(84)90041-9

    authors： Frindel E,Vendrely C

    更新日期：1984-01-01 00:00:00

  • In the absence of clinically significant graft vs. host disease, myeloablative conditioning may allow an effective graft vs. leukaemia effect.

    abstract：:In AML, prevention of GvHD leads to better tolerance of myeloablative therapy. 66 individuals with AML in CR underwent myeloablative conditioning and transplantation with allogeneic PBPC grafts. Median presentation age was 44.5 years. Karyotyping was intermediate in 48% and of unfavourable risk in 36%. For GvHD prophy...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.leukres.2011.06.039

    authors： Novitzky N,Thomas V

    更新日期：2012-01-01 00:00:00

  • Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics.

    abstract：:The aim of the study was to investigate the expression of MIP-1 alpha and sclerostin in bone marrow of patients with multiple myeloma (MM), the possible association of the sclerostin and MIP-1 alpha with MBD and the clinical characteristics. 53 patients (29 M, 24 F), median age 64 years was studied. MIP-1 alpha, scler...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2014.02.010

    authors： Wang XT,He YC,Zhou SY,Jiang JZ,Huang YM,Liang YZ,Lai YR

    更新日期：2014-05-01 00:00:00

  • ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target.

    abstract：:Nasal-type natural killer/T-cell (NK/T-cell) lymphomas are subtypes of non-Hodgkin's lymphoma (NHL), which are typically more clinically aggressive. There is, however relatively little understanding of nasal-type NK/T-cell lymphoma molecular pathogenesis. Thus, in this study we applied RNA sequencing to systematically...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.10.001

    authors： Zhang X,Zhao L,Li X,Wang X,Li L,Fu X,Sun Z,Li Z,Nan F,Chang Y,Zhang M

    更新日期：2015-12-01 00:00:00

  • Induction of differentiation of myelogenous leukemia cells by humulone, a bitter in the hop.

    abstract：:The active form of vitamin D, 1alpha,25-dihydroxyvitamin D3 (VD3), inhibits proliferation and induces differentiation of myelomonocytic leukemia cells, but its clinical use is limited by the adverse effect of hypercalcemia. VD3 mobilizes calcium stores from bone by inducing the dissolution of bone mineral and matrix. ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(98)00046-0

    authors： Honma Y,Tobe H,Makishima M,Yokoyama A,Okabe-Kado J

    更新日期：1998-07-01 00:00:00

  • Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia.

    abstract：:We present our first experiences with determination of minimal residual disease (MRD) based on patient specific Flt3-ITD (internal tandem duplication) mutations. We analysed MRD status of 11 AML patients in a retrospective investigation and its potential impact on the follow up of these patients. In five out of six pa...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2004.12.001

    authors： Scholl S,Loncarevic IF,Krause C,Kunert C,Clement JH,Höffken K

    更新日期：2005-07-01 00:00:00

  • Susceptibility of acute myeloid leukemia (AML) cells from clinically resistant and sensitive patients to daunomycin (DNR): assessment in vitro after stimulation with colony stimulating factors (CSFs).

    abstract：:Chemosensitivity of purified AML blasts to daunomycin was examined under conditions of CSF stimulation and compared with clinical outcome of DNR combination chemotherapy. AML blasts from 16 patients were purified, incubated serum-free in the presence of optimal concentrations of a complete cocktail of IL-3, GM-CSF and...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(90)90166-7

    authors： Santini V,Nooter K,Delwel R,Löwenberg B

    更新日期：1990-01-01 00:00:00

  • Molecular characterization and prognostic significance of FLT3 in CML progression.

    abstract：:To characterize the molecular mechanisms involved in the transition from the chronic phase to blast crisis in chronic myelogenous leukemia (CML), gene expression profiles of leukemic cells from patients in the chronic and blast crisis phases were analyzed using an 8.7K cDNA chip and real-time PCR. A transient transfec...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.11.008

    authors： Kim KI,Park J,Ahn KS,Won NH,Kim BK,Shin WG,Yoon SS,Oh JM

    更新日期：2010-08-01 00:00:00

  • 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.

    abstract：:3q26.2/EVI1 rearrangements resulting in EVI1 overexpression play an important role in leukemogenesis and are associated with treatment resistance and a poorer prognosis in patients with acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia and BCR-ABL negative myeloproliferative neoplasms. In this...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2017.12.004

    authors： Hu Z,Hu S,Ji C,Tang Z,Thakral B,Loghavi S,Medeiros LJ,Wang W

    更新日期：2018-02-01 00:00:00

  • Heterogeneity of peripheral blood T-cell colony-forming cells in patients with T-cell malignancies.

    abstract：:Some peripheral blood clonogenic T-cells from patients with T-cell malignancies can generate colonies in methylcellulose in the absence of added growth factors or mitogen stimulation (T-CFCs). T-CFC from these patients were also able to form colonies in semi-solid media in the presence of added growth factors (T-CFCi)...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(84)90057-2

    authors： Georgoulias V,Auclair H,Jasmin C

    更新日期：1984-01-01 00:00:00

  • Increased peripheral stem cell pool in MDS: an indication of disease progression?

    abstract：:The colony-forming capacity of the peripheral blood stem/progenitor cells (PBSC) in different forms of myelodysplastic syndrome (MDS) was investigated. In most cases of refractory anemia (RA) the colony growth of PBSC was definitely reduced as compared to the controls. However, in RA with unfavorable chromosomal aberr...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(01)00064-9

    authors： Vehmeyer K,Haase D,Alves F

    更新日期：2001-11-01 00:00:00

  • A novel sporadic Burkitt lymphoma cell line (BLUE-1) with a unique t(6;20)(q15;q11.2) rearrangement.

    abstract：:We report the establishment and characterization, including HLA-typing, immunophenotypic and molecular cytogenetic analysis, of a novel EBV-negative cell line (BLUE-1) derived from adult relapsed sporadic Burkitt lymphoma. BLUE-1 carries the pathognomonic t(8;14)(q24;q32) effecting MYC/IgHJ fusion and a novel t(6;20)(...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.03.026

    authors： Burmeister T,Macleod RA,Reinhardt R,Mansmann V,Loddenkemper C,Marinets O,Drexler HG,Thiel E,Blau IW

    更新日期：2006-11-01 00:00:00